A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma
2018
The Journal of the National Comprehensive Cancer Network
Preserved Fulltext
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell malignancy involving the spleen and bone marrow. Various cytogenetic abnormalities with prognostic value have been identified in SMZL. Complexity of karyotype, 14q aberrations, and TP53 deletions have been found to be poor prognostic indicators. We report an unusual case of SMZL with a complex karyotype including 17p deletion, primarily refractory to 2 chemoimmunotherapy regimens, that responded well to treatment with
doi:10.6004/jnccn.2017.7034
pmid:29523661
fatcat:3gukneq4cvgjnnzuearscc2tcm